What’s a late-stage IL-23 drug worth these days? We’re about to find out

We’ve seen how much Brent Saun­ders paid for his pipeline drugs while CEO of Al­ler­gan. Now we’ll get a demon­stra­tion of what they’re worth on the open mar­ket.

In an SEC fil­ing Tues­day the com­pa­ny — be­ing snapped up by Ab­b­Vie — said it will sell their Phase III IL-23 drug brazikum­ab to sat­is­fy the FTC’s an­titrust con­cerns. And that is be­ing shopped along with the mar­ket­ed ther­a­py Zen­pep.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER